Abstract
Monoclonal antibodies (MAbs) exhibit complex pharmacokinetics (PK) and pharmacodynamics (PD, response) against tumor necrosis factor (TNF). Many factors impact anti-TNF MAb PK, altering MAb clearance and therefore the half-life: albumin, weight (particularly, obesity), disease (severity, stage and co-morbidities) and concomitant administration of immunosuppressants (e.g. methotrexate). These factors can alter MAb exposure, impacting on the likelihood of clinical response. Formation of anti-drug antibodies (ADAs) is another potential factor that can affect MAb PK. Factors impacting the likelihood of developing ADA are classified as patient-related (concomitant immunosuppressants, prior ADA against other anti-TNF MAb) or product-related (structure, manufacturing process, aggregate formation, route of administration and dosing regimen). Repeated episodic exposure can induce ADAs, shortening the effective treatment interval. Avoiding intervals where anti-TNF MAbs are non-measurable is important for efficacy and may delay onset of ADAs. Thus, patients whose factors predispose them to having faster clearance (or short half-life) such as severe disease, low albumin or high body weight may need shorter dose intervals to reduce the likelihood of intermittent exposure. ADAs can have no effect or can impact efficacy through MAb binding, thus inhibiting its function or potentially causing hypersensitivity reactions (PD). ADA can also increase MAb clearance (PK). Because of their impact on MAb clearance, ADAs have been linked to lower serum drug concentrations, potentially negatively impacting clinical response. ADAs have been reported for biologics in most therapeutic areas. ADAs are well documented in clinical studies due to the Food and Drug Administration and the European Medicines Agency recommendations regarding testing and impact of immunogenicity. Lastly, the dose metrics (e.g. mg vs. mg/kg) can cause issues as well. MAbs such as infliximab are dosed on a mg/kg basis, which commonly results in low concentrations in patients with low body weight. Conversely MAbs such as adalimumab are administered as a flat (mg) dose, which can result in low concentrations in high weight patients.
Journal Section:
Biological and Pharmacokinetics: What Clinicians Need to Know
References
1.
Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
2.
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG: Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-1479.
3.
Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(suppl 1):i16-i35.
4.
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF: Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-653.
5.
Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR: Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
6.
Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study: Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19:478-487.
7.
Imaeda H, Takahashi K, Fujimoto T, et al: Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014;49:100-109.
8.
Billioud V, Sandborn WJ, Peyrin-Biroulet L: Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-684.
9.
Wang W, Wang EQ, Balthasar JP: Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-558.
10.
Waldmann TA, Strober W: Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
11.
Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, Zhou H: A Population-Based Pharmacokinetic Pooled Analysis of Infliximab in Pediatrics. San Diego, ACCP National Meeting, 2012.
12.
Fasanmade AA, Adedokun OJ, Blank M, et al: Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011;33:946-964.
13.
Mould DR: Using pharmacometrics in the development of therapeutic biological agents; in Ette E, Williams P (eds): Pharmacometrics: The Science of Quantitative Pharmacology. John Wiley & Sons Hoboken, 2007.
14.
Ordás I, Mould DR, Feagan BG, Sandborn WJ: Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635-646.
15.
Mould DR, Baumann A, Kuhlmann J, et al: Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-291.
16.
Lowe PJ, Tannenbaum S, Gautier A, Jimenez P: Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009;68:61-76.
17.
Mould DR, Green B: Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010;24:23-39.
18.
Beeken WL, Busch HJ, Sylwester DL: Intestinal protein loss in Crohn's disease. Gastroenterology 1972;62:207-215.
19.
Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG: Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem 1992;30:197-202.
20.
Brandse JF, Wildenberg M, de Bruyn JR, et al: Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. Gastroenterology 2013;144:S7763.
21.
Brambell FW, Hemmings WA, Morris IG: A theoretical model of gamma-globulin catabolism. Nature 1964;203:1352-1354.
22.
Telleman P, Junghans RP: The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology 2000;100:245-251.
23.
Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al: MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 2001;166:3266-3276.
24.
Morell A, Terry WD, Waldmann TA: Metabolic properties of IgG subclasses in man. J Clin Invest 1970;49:673-680.
25.
Marks J: Antibody formation in myelomatosis. J Clin Pathol 1953;6:62-63.
26.
Ternant D, Paintaud G: Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5(suppl 1):S37-S47.
27.
Cohen-Solal JF, Cassard L, Fridman WH, Sautes-Fridman C: Fc gamma receptors. Immunol Lett 2004;92:199-205.
28.
Reddy MP, Kinney CA, Chaikin MA, et al: Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 2000;164:1925-1933.
29.
Mortensen DL, Prabhu S, Stefanich EG, Kadkhodayan-Fischer S, Gelzleichter TR, Baker D, Jiang J, Wallace K, Iyer S, Fielder PJ, Putnam WS: Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs 2012;4:724-731.
30.
Louis E, et al: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004;19:511-519.
31.
Weiner LM: Monoclonal antibody therapy of cancer. Semin Oncol 1999;26:43-51.
32.
Schellekens H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462.
33.
Brinks V, Jiskoot W, Schellekens H: Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011;28:2379-2385.
34.
Kijanka G, Jiskoot W, Schellekens H: Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res 2013;30:1553-1560.
35.
Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-674.
36.
Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-715.
37.
Colombel JF, Sandborn WJ, Reinisch W, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395.
38.
Feagan BG, McDonald JW, Panaccione R, et al: Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014;146:681-688.e1.
39.
Ben-Horin S, Waterman M, Kopylov U, et al: Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:444-447.
40.
Porter CJ, Charman SA: Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000;89:297-310.
41.
Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A: The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 2007;67:759-765.
42.
Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-2668.
43.
Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, Nunes CN, Johnson CV, Yin KC, Groff M, Zou Y, Liu L, Hamuro L, Prueksaritanont T: Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 2012;40:952-962.
44.
Dubinsky MC, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, Kim C, Glessner J, Targan SR, McGovern DP, Taylor KD, Rotter JI: Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric Inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1357-1366.
45.
Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612-1619.
46.
Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-1610.
47.
Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
48.
Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.
49.
Maser EA, Villela R, Silverberg MS, Greenberg GR: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-1254.
50.
Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S: Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-84.e2.
51.
Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X: Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:423-431.e1.
52.
Shargel L, Yu A: Applied Biopharmaceutics & Pharmacokinetics, ed 6, 2012.
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
